Arthur Winston
Affiliations: | Tufts University, Boston |
Area:
Management Business Administration, Industrial PsychologyGoogle:
"Arthur Winston"Mean distance: 53433
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Churchill D, Waters L, Ahmed N, et al. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Hiv Medicine. 17: s2-s104 |
| Underwood J, Winston A. (2016) Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals. Current Hiv/Aids Reports |
| Winston A, Stöhr W, Antinori A, et al. (2015) Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Hiv Medicine |
| Ashby J, Foster C, Garvey L, et al. (2015) Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. Hiv Clinical Trials. 16: 81-7 |
| Vera JH, Jackson A, Dickinson L, et al. (2015) The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Hiv Clinical Trials. 16: 39-42 |
| Arenas-Pinto A, Winston A, Stöhr W, et al. (2014) Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. Plos One. 9: e103498 |
| Williams I, Churchill D, et al. (2014) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). Hiv Medicine. 15: 1-85 |
| Garvey LJ, Pavese N, Politis M, et al. (2014) Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids (London, England). 28: 67-72 |
| Winston A, Arenas-Pinto A, Stöhr W, et al. (2013) Neurocognitive function in HIV infected patients on antiretroviral therapy. Plos One. 8: e61949 |
| Mora-Peris B, Croucher A, Else LJ, et al. (2013) Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. The Journal of Antimicrobial Chemotherapy. 68: 1348-53 |